RecruitingNCT00470327
A Study of the Natural Progression of Interstitial Lung Disease (ILD)
Sponsor
University of Chicago
Enrollment
4,000 participants
Start Date
Sep 1, 2005
Study Type
OBSERVATIONAL
Conditions
Summary
We propose to acquire data and blood samples on all patients being cared for by the Interstitial Lung Disease (ILD) program. Additionally, we will collect data and blood samples from a control group for comparator purposes. In doing so, we will be able to describe the "phenotypic" expression of these diseases.
Eligibility
Min Age: 18 Years
Inclusion Criteria1
- Interstitial lung disease
Exclusion Criteria1
- Does not have Interstitial lung disease
Interested in this trial?
Get notified about updates and connect with the research team.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT00470327
Related Trials
A Study to Find an Efficacious and Safe Dose of CHF10067 (Zampilimab) in Participants With Idiopathic Pulmonary Fibrosis
NCT075169511 location
Study to Evaluate the Efficacy, Safety, and Tolerability of PIPE 791 in Subjects With Idiopathic Pulmonary Fibrosis
NCT0728445950 locations
ATHN Transcends: A Natural History Study of Non-Neoplastic Hematologic Disorders
NCT0439862871 locations
Phase 2 Clinical Trial of MNKD-201 (Nintedanib Dry Powder Inhalation) in Patients With Idiopathic Pulmonary Fibrosis
NCT076798932 locations
Idiopathic Pulmonary Fibrosis (IPF)-Related Chronic Cough Reduction With Nalbuphine Extended-Release (NAL ER) Tablets
NCT076719115 locations